In men taking nitrates to treat cardiovascular disease (CVD), the concomitant use of phosphodiesterase type 5 inhibitors (PDE5i) to treat erectile dysfunction (ED) is associated with an increased risk of mortality and morbidity, according to a new analysis of Swedish national patient data.